Healthcare / Diagnostics & ResearchKOSDAQ
$1662.00
-111.00 (-5.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-233.8M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.5%
↓Gross Margin
59.5%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.7%
FCF CAGR
—
FCF margin
11.5%
FCF / Net income
-0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.64B · net income $-1.83B · FCF $1.23B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.64B | $10.64B | $10.02B | $9.81B | $11.21B |
| Net Income | $-1.83B | $-1.83B | $-3.75B | $-894.9M | $-8.11B |
| EBITDA | $-1.17B | $-1.17B | $-3.00B | $-172.3M | $-7.48B |
| EPS | -92.00 | -92.00 | -188.00 | -45.00 | -406.00 |
| Gross Margin | 59.5% | 59.5% | 58.0% | 50.0% | 45.9% |
| Operating Margin | -6.4% | -6.4% | -16.4% | -26.0% | -13.6% |
| Net Margin | -17.2% | -17.2% | -37.4% | -9.1% | -72.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.19 | 0.16 | 0.15 |
| Current Ratio | 2.02 | 2.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.23B | $1.23B | $-233.8M | $-2.51B | $-1.20B |
| Returns | |||||
| ROE | -10.5% | -10.5% | -19.5% | -3.9% | -33.5% |
| Valuation | |||||
| P/B | 1.90 | 1.90 | 2.92 | 2.61 | 3.50 |
| Growth & Yield | |||||
| Revenue Growth | 6.2% | 6.2% | 2.1% | -12.5% | — |
| EPS Growth | 51.1% | 51.1% | -317.8% | 88.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-188.00 → -92.00
Residual
-31.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.